Vaccines and Immunization: Measles, Mumps, and Rubella
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Epidemiology and Vaccination".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 577
Special Issue Editor
Special Issue Information
Dear Colleagues,
Measles, mumps, and rubella are viral diseases with many complications. Measles can become severe and often lead to death, mumps are associated with hearing loss, and rubella infection in pregnant women can cause fetal infection and CRS at high rates. Fortunately, the number of cases has dropped dramatically in countries and regions where vaccines are widely used. However, the COVID-19 pandemic, poverty, and conflicts have significantly impacted vaccination efforts. In areas where immunization rates have declined, a resurgence of these diseases is also affecting neighboring countries. Moreover, while measles, mumps, and rubella have typically been viewed as childhood diseases, recent epidemiological trends show that their impact extends to adults and the elderly. This Special Issue aims to explore the future of these diseases, focusing on advancements in understanding their pathology and virology, changes in the epidemiological landscape, and progress in developing future vaccines.
We look forward to your contributions and insights on this important topic.
Dr. Nobuhiko Okabe
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- measles
- mumps
- rubella
- SSPE
- hearing loss
- CRS
- immune mechanism
- epidemiology
- resurgence
- life-course immunization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
